戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 an monitor the response of these cells to an immunomodulatory drug.
2 olerant of, >=1 proteasome inhibitor and >=1 immunomodulatory drug.
3 t that included a proteasome inhibitor or an immunomodulatory drug.
4 hich suggests the novel use of ICOS-Fc as an immunomodulatory drug.
5 d its occurrence as a side effect of certain immunomodulatory drugs.
6 argets for the development of new classes of immunomodulatory drugs.
7 may improve the therapeutic potential of the immunomodulatory drugs.
8  hematopoietic stem cell transplantation and immunomodulatory drugs.
9 and immune-stimulatory effects compared with immunomodulatory drugs.
10  including in disease that was refractory to immunomodulatory drugs.
11 host immune system can have broad effects on immunomodulatory drugs.
12 ost anti-cancer immunity and the efficacy of immunomodulatory drugs.
13 including systemic steroids, remdesivir, and immunomodulatory drugs.
14 ant cytokines, cell therapies, vaccines, and immunomodulatory drugs.
15 or GSPT1] whose ubiquitylation is induced by immunomodulatory drugs.
16 exposed to bortezomib, alkylators, and other immunomodulatory drugs.
17  NPM1 mutation and predicted the response to immunomodulatory drugs.
18 ous treatment with proteasome inhibitors and immunomodulatory drugs.
19 t is refractory to proteasome inhibitors and immunomodulatory drugs.
20 lation followed by a systemic application of immunomodulatory drugs.
21  HIV, including use of anti-inflammatory and immunomodulatory drugs.
22 use of interactors of the ICOS:B7h system as immunomodulatory drugs.
23  of thalidomide and member of a new class of immunomodulatory drugs.
24 lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an an
25  the capacity to co-encapsulate two types of immunomodulatory drugs, a chemokine and an RNAi sequence
26 s that could be augmented when combined with immunomodulatory drugs, a combination therapy the author
27 ne response against influenza virus using an immunomodulatory drug, AAL-R, provides significant prote
28                           Lenalidomide is an immunomodulatory drug active as salvage therapy for chro
29                     We hypothesized that the immunomodulatory drug alefacept would result in targeted
30  understanding how rapamycin functions as an immunomodulatory drug and for the development of complem
31 ble refractory to a proteasome inhibitor and immunomodulatory drug and had received prior proteasome
32 ease refractory to proteasome inhibitors and immunomodulatory drugs and 64% had disease refractory to
33 ts enrolled, all having prior bortezomib and immunomodulatory drugs and a median of 5 prior regimens.
34 served immune signature was modifiable using immunomodulatory drugs and lifestyle changes.
35 erful, generalizable strategy for generating immunomodulatory drugs and mechanistic tool compounds.
36                             Although several immunomodulatory drugs and molecules are available, most
37  lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and re
38        With the introduction of novel agents-immunomodulatory drugs and proteasome inhibitors-respons
39 nd clinical studies with thalidomide and the immunomodulatory drugs and their application in differen
40 , epigenetic targeting agents are attractive immunomodulatory drugs and will have major impacts on im
41 r lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antib
42 ug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody.
43 ug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody.
44 and had received prior proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy.
45 ines including a proteasome inhibitor and an immunomodulatory drug, and had an ECOG performance statu
46 ble refractory to a proteasome inhibitor and immunomodulatory drug, and had received a proteasome inh
47 -refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inh
48 th >/=2 prior lines of therapy, including an immunomodulatory drug, and patients who had progressed o
49 mbinations, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibod
50 ents, purine analogs, proteasome inhibitors, immunomodulatory drugs, and mammalian target of rapamyci
51 t regimens containing proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
52 -care agents including anti-CD38 antibodies, immunomodulatory drugs, and proteasome inhibitors improv
53 efractory to both a proteasome inhibitor and immunomodulatory drug; and had an Eastern Cooperative On
54 spite treatment with a proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and noncellul
55                           Lenalidomide is an immunomodulatory drug approved in the United States for
56                                              Immunomodulatory drugs are a class of drugs approved for
57                                          The immunomodulatory drugs are a novel, nonteratogenic class
58                                              Immunomodulatory drugs are active agents in light-chain
59 er, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulatory drugs are also likely to have a place i
60 ultiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromb
61                             Although several immunomodulatory drugs are available for multiple sclero
62 gests that traditional immunosuppressive and immunomodulatory drugs are certainly effective in polymy
63 sing because of the HIV pandemic and because immunomodulatory drugs are increasingly used to treat au
64                                      Several immunomodulatory drugs are used for the management of LN
65  and its novel T cell costimulatory analogs (immunomodulatory drugs) are currently being assessed in
66 ese results warrant further investigation of immunomodulatory drugs as maintenance in high-risk patie
67          This has led to growing interest in immunomodulatory drugs as potential treatments.
68                           Pom-Dex, a doublet immunomodulatory drug-based regimen, is active and well
69                                              Immunomodulatory drugs bind to cereblon (CRBN) to confer
70 as well as different biological responses to immunomodulatory drugs can be expected to contribute to
71                       Evidence suggests that immunomodulatory drugs can directly act on glomerular ep
72                                              Immunomodulatory drugs can inhibit bacterial growth, yet
73 apse are common after surgical resection and immunomodulatory drugs can maintain long-term remission.
74 vated T lymphocytes, and indicate that novel immunomodulatory drugs can serve to inhibit the pathogen
75 ciated gene signatures to identify potential immunomodulatory drug candidates.
76 In this study, we assessed the ability of an immunomodulatory drug (CC-4047/ACTIMID) to prime a tumor
77 ole for continuous proteasome inhibitors and immunomodulatory drug combination maintenance therapy fo
78 , respectively) could represent an effective immunomodulatory drug combination.
79 tion in the era of proteasome inhibitors and immunomodulatory drugs combinations, demonstrating a sig
80                                              Immunomodulatory drugs could contribute to a functional
81 veraged for controlled release to achieve an immunomodulatory drug delivery system.
82 s to infection and optimizing strategies for immunomodulatory drug delivery.
83              The class of compounds known as immunomodulatory drugs derived from thalidomide is devel
84 restriction, promoting potential avenues for immunomodulatory drug design for antiviral or anti-infla
85               The lack of recent advances in immunomodulatory drug development, together with advance
86                    Others have reported that immunomodulatory drugs (e.g., thalidomide and lenalidomi
87 he therapeutic treatment of MP rats with the immunomodulatory drug fingolimod promotes both antiepile
88 rferon alpha (IFNalpha) is the only approved immunomodulatory drug for chronic hepatitis B treatment,
89                           Methotrexate is an immunomodulatory drug for patients with Crohn's disease.
90         Fingolimod (FTY720), an FDA-approved immunomodulatory drug for treating multiple sclerosis, i
91 f concept for using tissue explants to study immunomodulatory drugs for asthma.
92 tion of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascul
93                                        While immunomodulatory drugs for most medical conditions are u
94 verse events, and the potential to repurpose immunomodulatory drugs for other comorbidities to enhanc
95  development of more effective and selective immunomodulatory drugs for particular subsets of patient
96                                  The role of immunomodulatory drugs for relapses needs further study.
97 ze after treatment with anti-inflammatory or immunomodulatory drugs given for AOSD.
98                         To date, no specific immunomodulatory drug has proven efficacy in targeting t
99 The introduction of proteasome inhibitor and immunomodulatory drugs has considerably changed the trea
100            Lenalidomide, a second generation immunomodulatory drug, has shown substantial remitting a
101                                     Although immunomodulatory drugs have been used extensively in the
102                   Thalidomide analogues, the immunomodulatory drugs have increased potency and have d
103                     Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma
104                          Thalidomide and its immunomodulatory drug (IMiD) analogs, lenalidomide, and
105           Patients had RRMM refractory to an immunomodulatory drug (IMiD) and a proteasome inhibitor
106 us stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance.
107                                              Immunomodulatory drug (IMiD) resistance is a key clinica
108                                          The immunomodulatory drug (IMiD) thalidomide and its structu
109 he CoMMpass study, all of which had received immunomodulatory drug (IMiD) therapy.
110                           Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid m
111 ory effects of a more potent analog of Thal, immunomodulatory drug (IMiD), on T cells.
112 and SMARCA2/4 inhibitors remain effective in immunomodulatory drug (IMiD)-resistant MM cells.
113 result, PKCalpha conferred resistance to the immunomodulatory drugs (IMiD) lenalidomide in a cereblon
114 including a proteasome inhibitor [PI] and an immunomodulatory drug [IMiD]) or were double refractory.
115                           Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in
116                                        Early immunomodulatory drugs (IMiDs(TM)) target Ikaros and Aio
117             The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multi
118                  Ikaros degraders, including immunomodulatory drugs (IMiDs) and cereblon E3 ligase mo
119 essential binding protein of the widely used immunomodulatory drugs (IMiDs) and novel CRBN E3 ligase
120                          The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors
121           Patients were pretreated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors
122 r survival rate that is usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors
123                                              Immunomodulatory drugs (IMiDs) are a major class of drug
124                                              Immunomodulatory drugs (IMiDs) are important for the tre
125 argets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor eff
126                                              Immunomodulatory drugs (IMiDs) have markedly improved pa
127 understand the molecular mechanisms by which immunomodulatory drugs (IMiDs) induce thrombocytopenia.
128                                          The immunomodulatory drugs (IMiDs) lenalidomide and pomalido
129                                          The immunomodulatory drugs (IMiDs) lenalidomide and pomalido
130                                              Immunomodulatory drugs (IMiDs) lenalidomide and pomalido
131 vatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effec
132                                          The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide
133 Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to
134             Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remissi
135  cereblon (CRBN) protein include widely used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase
136  of active agents, proteasome inhibitors and immunomodulatory drugs (IMiDs), resulting in a significa
137 target for a class of small molecules termed immunomodulatory drugs (IMiDs).
138 ide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).
139 5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc fin
140 ssociation of LIS with the use of novel oral immunomodulatory drugs (IMiDs; lenalidomide and thalidom
141 tation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively.
142 mor activity of Thal and its potent analogs (immunomodulatory drugs [IMiDs]).
143  anti-MM activity of Thal and its analogues (immunomodulatory drugs, IMiDs) on MM cells was demonstra
144 ng the LNP platform to deliver more than one immunomodulatory drug in a cell-specific manner to manag
145  the safety and efficacy of other repurposed immunomodulatory drugs in autoimmune diseases.
146 f indatuximab ravtansine in combination with immunomodulatory drugs in patients with relapsed or refr
147     These lessons highlight the potential of immunomodulatory drugs in psychiatric disorders while em
148 a were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes.
149 eresting template in the quest to design new immunomodulatory drugs in the therapy of immune-related
150 ta, and clinical implications for use of the immunomodulatory drugs in the treatment of myelodysplast
151      Moreover, there is a robust pipeline of immunomodulatory drugs in various stages of development
152 efit from treatment with previously approved immunomodulatory drugs, including glucocorticoids such a
153                                        IMiDs immunomodulatory drugs, including lenalidomide and pomal
154 ught to determine the applicability of a new immunomodulatory drug inhibiting the store-operated calc
155 s the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infec
156 es in human P450-catalysed metabolism of the immunomodulatory drug leflunomide, which likewise underg
157                   Combining WT1-TCB with the immunomodulatory drug lenalidomide further enhanced anti
158                                          The immunomodulatory drug lenalidomide had direct anti-proli
159                                          The immunomodulatory drug lenalidomide is widely used for tr
160 , we studied the clinical significance of an immunomodulatory drug lenalidomide on SGN-40-induced cyt
161                   Of clinical relevance, the immunomodulatory drug lenalidomide prevented the inducti
162                                          The immunomodulatory drug lenalidomide shows therapeutic eff
163      The proteasome inhibitor bortezomib and immunomodulatory drug lenalidomide targeted MM cells in
164 his T-cell defect was demonstrated using the immunomodulatory drug lenalidomide, which completely res
165 atment of both FL cells and T cells with the immunomodulatory drug lenalidomide.
166  T-cell signaling, which was reversed by the immunomodulatory drug lenalidomide.
167 iquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.
168 uton tyrosine kinase inhibitor ibrutinib and immunomodulatory drugs (lenalidomide or pomalidomide) ha
169 ezomib), mTOR inhibitors (temsirolimus), and immunomodulatory drugs (lenalidomide) have recently been
170 ines of therapy, including bortezomib and an immunomodulatory drug; lenalidomide-refractory patients
171 , an aberrant immune response, or the use of immunomodulatory drugs, many of the rheumatic diseases a
172                                              Immunomodulatory drugs may have efficacy for depressive
173 revious regimens including bortezomib and an immunomodulatory drug, median overall survival was 25.5
174 f this approach can monitor the effect of an immunomodulatory drug on brain-infiltrating leukocytes.
175         Most patients could be salvaged with immunomodulatory drugs or radiation.
176 to be treated by 3 or more immunosuppressive/immunomodulatory drugs (OR, 4.07; 95% CI, 1.17-14.14; P
177 therapy (including proteasome inhibitors and immunomodulatory drugs), or were refractory to both prot
178 o had received treatment with bortezomib, an immunomodulatory drug, or both, or who were receiving a
179 herapy, including a proteasome inhibitor and immunomodulatory drug, or were double refractory to both
180 rapy, including a proteasome inhibitor or an immunomodulatory drug, or were double refractory.
181                                              Immunomodulatory drugs, particularly hydroxychloroquine
182 ients in reports published previously-before immunomodulatory drugs-patients who do not achieve parti
183 ight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently a
184 e safety and therapeutic activity of another immunomodulatory drug, pomalidomide.
185 iple-class refractory disease (refractory to immunomodulatory drugs, proteasome inhibitors, and CD38
186                          The introduction of immunomodulatory drugs, proteasome inhibitors, and CD38-
187  refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab
188                                          Our immunomodulatory drug regimen includes induction with an
189    They also suggest that clinical trials of immunomodulatory drugs related to CTLA4 and that are alr
190 thdrawal responded; 7 patients on additional immunomodulatory drugs remain in steroid-free remission
191                    With a targeted approach, immunomodulatory drugs represent an important step towar
192 represent an alternative therapy to overcome immunomodulatory drug resistance in MM.
193 vator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro.
194 ome and discriminates patient subsets in who immunomodulatory drugs should be tested.
195                                          The immunomodulatory drugs show exciting erythropoietic acti
196   Indatuximab ravtansine in combination with immunomodulatory drugs shows preliminary antitumor activ
197 circumvent the immune system and function as immunomodulatory 'drug stores' to influence multiple cel
198                                              Immunomodulatory drugs such as baricitinib, tocilizumab
199  the teratogenic and antitumor activities of immunomodulatory drugs such as thalidomide, lenalidomide
200  with novel agents, including bortezomib and immunomodulatory drugs, such as lenalidomide.
201 and systemic lupus erythematosus, as a novel immunomodulatory drug target controlling T cell inflamma
202                                          The immunomodulatory drug thalidomide is the treatment of ch
203                     These agents include the immunomodulatory drugs thalidomide and lenalidomide, the
204 tive yet have low toxic effects, such as the immunomodulatory drugs thalidomide and lenalidomide.
205                                          The immunomodulatory drugs, thalidomide and lenalidomide, an
206               EtOH provides an example of an immunomodulatory drug that acts at least in part by modi
207             Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic act
208                        Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but
209  has emerged supporting the role of GA as an immunomodulatory drug that regulates T-cell function.
210                      Lenalidomide is an oral immunomodulatory drug that repairs antitumor T-cell func
211  poly (ADP-ribose) polymerase-1 and mTOR and immunomodulatory drugs that are in the early stages of c
212          JAK inhibitors represent a class of immunomodulatory drugs that inhibit signaling by multipl
213 cluding new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural reme
214 tional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies.
215 2, in particular, could be used as selective immunomodulatory drugs to inhibit CD4(+) T cells during
216 ationale for combining TIGIT inhibition with immunomodulatory drugs to prevent myeloma progression af
217 ting immune responses and can be targeted by immunomodulatory drugs to treat a variety of immune diso
218 interferon (IFN-alpha) is the only available immunomodulatory drug, to which only a minority of chron
219 llowing variables: prior VTE, prior surgery, immunomodulatory drug use, abnormal metaphase cytogeneti
220 to the most recent proteasome inhibitors and immunomodulatory drugs used, and 103 (97%) were refracto
221             Pomalidomide, a third-generation immunomodulatory drug, was proposed to induce fetal hemo
222 refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1
223        The administration of thalidomide, an immunomodulatory drug with antiangiogenic effects, is li
224                             Lenalidomide, an immunomodulatory drug with antineoplastic and antiprolif
225 we use the experimental medicine approach of immunomodulatory drug withdrawal in rheumatoid arthritis
226 fficiently compared to other quinoline-based immunomodulatory drugs within oncogenic DNA, particularl
227 5% CI, 0.47-0.99; P = .02) or treatment with immunomodulatory drugs (within-center aOR, 0.77; 95% CI,
228 hree), and status of previous treatment with immunomodulatory drugs (yes or no), and used permuted bl

 
Page Top